INTRODUCTION
Glycolysis is the metabolic pathway through which glucose is converted into pyruvate, with a net yield of 2 mol of ATP and NADH per mol of glucose used. In liver, where the glycolytic flux is low except when glucose concentrations are high or during anoxia, the main function of glycolysis is to provide substrates for anabolic processes. While glycolysis occurs in every tissue, gluconeogenesis is specific for the liver, the kidney and the small intestine. Gluconeogenesis supplies glucose to the body and provides a way to dispose of amino acids and lactate produced by erythrocytes and during muscle contraction. It is also a means of disposal for glycerol produced during lipolysis.
Liver glycolysis and gluconeogenesis share several enzymes which catalyse reactions that are close to equilibrium (reversible) under physiological conditions. On the other hand, three substrate cycles, i.e. the glucose/glucose 6-phosphate, fructose 6-phosphate/fructose 1,6-bisphosphate and phosphoenolpyruvate/pyruvate cycles, involve exergonic reactions that regulate the pace of glycolysis and gluconeogenesis. These reactions, which are maintained far from equilibrium, are catalysed by different enzymes in the glycolytic and gluconeogenic pathways. It is therefore not surprising that these key enzymes are the main targets of regulatory mechanisms. Short-term regulation involves both the supply of glycolytic or gluconeogenic substrates and the control of the catalytic properties of the enzymes through allosteric changes and phosphorylation [1, 2] . Long-term regulation in liver involves changes in gene expression and protein synthesis [3, 4] and is the subject of the present review.
Indeed, several mechanisms that restrict gene transcription to the liver and modulate it upon hormonal stimulation and nutrient supply have been unravelled. These mechanisms rely upon the interaction of nuclear proteins, called trans-acting factors, with cis-acting DNA sequences that belong to the gene considered. These sequences usually lie upstream from the transcription initiation (cap) site, in the promoter proper or at a distance that may reach several kilobases, in which case they are called enhancers (or silencers). The latter are sometimes found downstream from the cap site. Trans-acting factors are ubiquitous or 'tissue-enriched', and are distinct from the general transcription factors that directly assist RNA polymerase II through binding in the vicinity of the cap site. Some of them are hormone receptors, the activity of which is triggered by ligand binding. The five, well-characterized, classes of liver-enriched factors are listed in Table 1 . The ubiquitous factors that control the genes discussed here are listed in Table 2 . These genes code for glucokinase, 6-phosphofructo-2-kinase (PFK-2)/fructose-2,6-bisphosphatase (FBPase-2), pyruvate kinase and phosphoenolpyruvate carboxykinase (PEPCK), namely enzymes that control key steps, and for aldolase and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which are enzymes controlling reversible steps.
In the present paper, we will review the data pertaining to the transcriptional control of these genes in liver. We will describe first the glycolytic enzymes and then the gluconeogenic enzyme PEPCK. Aldolase B and GAPDH are discussed with the glycolytic enzymes, as they are hormonally controlled like the latter. The genes that code for the other enzymes of glycolysis and gluconeogenesis have not been studied in sufficient detail at the transcriptional level to warrant consideration here. We will focus on the relevant cis-acting regions and trans-acting factors in an attempt to assign them a role in the liver-specific transcription and (or) in the response to hormones and carbohydrates.
GLUCOKINASE
Hexokinases (EC 2.7.1.1.) catalyse the phosphorylation of glucose to glucose 6-phosphate. The liver contains four hexokinases (A to D or I to IV), glucokinase (hexokinase D or IV) being by far the predominant isoenzyme. Pancreatic cells also contain a glucokinase activity. However, the regulation of hepatic and fcell glucokinases differs in a way related to the functions of the two cell types. Whereas hepatic glucokinase modulates glucose uptake, fl-cell glucokinase may play the role of a glucose sensor (reviewed in [5] ). By controlling the rate of the glycolytic flux in f, cells, glucokinase determines the ATP:ADP ratio, which is postulated to affect insulin secretion. Hepatic and f-cell glucokinases therefore play a complementary role in glucose homoeostasis. In liver, the regulatory protein of glucokinase binds to and inhibits glucokinase in the presence of fructose 6-phosphate (reviewed in [6] ).
Gene organization
The differential regulation of liver and ,-cell glucokinases relies on a genic basis (reviewed in [7] ). The liver and ,-cell mRNAs are identical with the exception of their 5' end that codes for a different 15-amino-acid stretch. In the rat [8, 9] and in the human [10, 11] , there is a single glucokinase gene containing 11 exons Abbreviations used: AF, accessory factor; b-HLH, basic region/helix-loop-helix; C/EBP, CCAAT/enhancer-binding protein; COUP-TF, chicken ovalbumin upstream promoter-transcription factor; CRE, cyclic AMP response element; CREB, cyclic AMP response element-binding protein; DBP, Dbinding protein; FBPase-1, fructose-1,6-bisphosphatase; FBPase-2, fructose-2,6-bisphosphatase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GIRE, glucose/insulin response element; GRU, glucocorticoid-responsive unit; HNF, hepatocyte nuclear factor; IRE, insulin response element; IRS, insulin response sequence; NF-I, nuclear factor-I; NFY, nuclear factor Y; Oct-1, octamer factor-1; PEPCK, phosphoenolpyruvate carboxykinase; PFK-1, 6-phosphofructo-i-kinase; PFK-2, 6-phosphofructo-2-kinase; PKA, cyclic AMP-dependent protein kinase; PKC, protein kinase C; RAR, retinoic acid receptor; RARE, retinoic acid response element; STAT, signal transducer and activator of transcription; T3, tri-iodothyronine; T3R, T3 receptor; USF, upstream stimulating factor.
* To whom correspondence should be addressed. [14] . On the contrary, the three potential HNF-4 sites all fit well with the bipartite consensus which contains the TGGACT/CT/C and TGGCCC motifs [15] . One report [16] showed promoter activity between -87 and + 17 upon transfection of hepatocytes in culture; deletion of nucleotides -87 to -48 reduced promoter activity. This coincided with the removal of a potential HNF-4 site. A role for regulation by the CCAAT/enhancer-binding protein (C/EBP) has been proposed [17] . [8, [19] [20] [21] . This stimulation does not depend on extracellular glucose [20, 21] and occurs within 30 min [22] . No insulin response element (IRE) has been experimentally localized on the liver promoter, but O'Brien and Granner [23] pointed to the existence of a TGGTTCTTTG motif at -83 that resembles the negative insulin response sequence (IRS) TGGTGTTTTG of the PEPCK gene. Glucagon, acting via cyclic AMP, inhibits the stimulation by insulin [20] . The mechanism is unknown, but the dominance of glucagon over insulin suggests that insulin stimulation may consist of derepression. Indeed, Nouspikel and lynedjian [22] showed that phosphodiesterase inhibitors, which are expected to increase cyclic AMP concentrations, abolish insulin stimulation of transcription. However, it is unlikely that insulin acts by stimulating phosphodiesterase as insulin treatment does not change cyclic AMP concentrations [22] . In addition, okadaic acid, an inhibitor of protein phosphatases PPI and PP2A, abolishes the response to insulin. The protein synthesis inhibitor cycloheximide also blocks the response to insulin [21, 22] but, given the rapidity of the insulin effect, it is unlikely that insulin action is a secondary response. In fact, cycloheximide could act through a mechanism that does not involve protein synthesis inhibition [22] . Alternatively, cycloheximide could block the synthesis of a factor that acts co-operatively on the glucokinase gene with the mediator of insulin action. A similar mechanism regulates the glucocorticoidinducibility of the al-acid glycoprotein gene [24] . The effect of insulin might also involve protein kinase C (PKC), since a PKC inhibitor blocks insulin stimulation [21] . However, phorbol esters do not mimic the effects of insulin [7] . In cultured hepatocytes, dexamethasone and tri-iodothyronine (T3) enhance the stimulation by insulin [21, 25] . 
There are several PFK-2/FBPase-2 isoenzymes which differ in tissue distribution, molecular mass, catalytic properties and response to protein kinases (reviewed in [28, 29] ). The best characterized are the liver (L), skeletal muscle (M), heart (H), testis (T) and brain isoenzymes. The sequence of the L mRNA of several species is known [30] [31] [32] as well as that of the rat M-, T-and H-type mRNAs [33] [34] [35] [36] . In addition, a fetal (F)-type mRNA was recently identified [37] . Two [41] . Several DNAase I footprints that involve ubiquitous and liver-specific proteins ( Figure 1) were detected [41, 42] . Ubiquitous proteins were identified as nuclear factor-I (NF-I) (four sites), octamer factor-I (Oct-i) (one site) and poly(dG)-tract binding proteins. The latter correspond to SpI and to uncharacterized proteins (F. P. Lemaigre [37] . It is noteworthy that the F promoter was the first known non-viral DNA target for GABP.
Hormonal and nutritional regulation Glucocorticoids stimulate L-type mRNA transcription in rat liver in vivo [44] and in cultured hepatocytes [45] as well as in FAO rat hepatoma cells [46] . The M-type mRNA level increases in vivo in skeletal muscle when adrenalectomized rats are treated with triamcinolone [47] . By transient transfection, Lange et al. [48] localized a glucocorticoid-responsive unit (GRU) in the intron located 3' of exon IL. This GRU contains two glucocorticoid-receptor-binding sites and a potential NF-I site. The GRU behaved as an enhancer when put upstream of the L or M promoter. This suggests that this GRU modulates in vivo the activity of both promoters. In FTO-2B cells, dexamethasone stimulates the synthesis of an mRNA [49] that appears to correspond to the F-type mRNA. We therefore believe that glucocorticoids also stimulate transcription from the F promoter.
Liver PFK-2/FBPase-2 mRNA levels increase in hypothyroid rats upon treatment with T3 [50] . In cultured rat hepatocytes, thyroid hormone has no effect on its own but potentiates the glucocorticoid induction [45] . Whether this reflects transcriptional or post-transcriptional regulation is unknown.
Glucagon, acting via cyclic AMP, and insulin exert opposite short-term effects on PFK-2/FBPase-2 activity (reviewed in [28] ); however, long-term regulation has been documented as well. Glucagon inhibits transcription from the L promoter and destabilizes the L mRNA in vivo [51] . In fasted or diabetic rats, refeeding or insulin treatment increases PFK-2/FBPase-2 mRNA concentration in liver after 24-48 h [52] [53] [54] . Cifuentes et al. [49] and Espinet et al. [46] [40] identified in liver chromatin five DNAase I-hypersensitive sites, two of which could correspond to other regulatory regions of gene A. Indeed, one site points to the M promoter, another to the L promoter, and a third co-localizes with the GRU described by Lange et al. [48] . A fourth site is centred on the -1000 region of the L promoter and the fifth in the intron located 3' of exon 1L, 500 bp upstream of the GRU.
ALDOLASE
This enzyme (EC 4.1.2.13) converts fructose 1,6-bisphosphate into glyceraldehyde 3-phosphate. It participates in glycolysis and gluconeogenesis and is also an enzyme of fructose metabolism. Aldolase is a tetramer for which three subunit types, encoded by three different genes, have been described. The aldolase A subunit is ubiquitously distributed but is very abundant in muscle. Aldolase C is present in brain, fetal tissues and cancer cells. Aldolase B is detected only in liver, in kidney proximal tubular cells and in enterocytes. We limit ourselves to aldolase B expression since this isoenzyme accounts for 98 % ofliver aldolase activity.
Gene organization and tissue-specffic control
The structures of the rat, human and chicken aldolase B genes have been determined [56] [57] [58] . In the three species the gene spans 15 kb and contains nine exons downstream of a single promoter. The regulatory elements and the transcription-factor-binding sites of the rat aldolase B promoter have been investigated and their function was analysed in isolated hepatocytes and in hepatoma cells [59] [60] [61] [62] . Figure 1 shows the topographical organization of the regulatory elements. The distal element (DE in Figure 1 ) behaves as a negative regulatory sequence since its deletion increases reporter gene activity in transfection experiments. The proteins that bind to this element have not been characterized. The proximal element (PE in Figure 1 ), whose function is unknown, corresponds to a region protected against DNAase I in footprinting experiments. Recombinant C/EBPa binds to the C/EBP site (referred to as 'C' box) and competing oligonucleotides known to bind C/EBP reduce transcription activity in experiments in vitro. Overexpression of C/EBPa or of the D-binding protein (DBP) in transfection stimulates promoter activity, demonstrating that C/EBP-related proteins might regulate the aldolase B promoter. Nuclear factor Y (NFY) and other CCAAT-binding factors bind to the so-called 'B' box, as assessed by oligonucleotide competition experiments. The function of this box is unclear. The liver-specific transcription activators HNF-1 and HNF-3 bind in a mutually exclusive way in a region referred to as the 'A' box. While the two proteins are detected in bandshift experiments, preferential HNF-3 binding is seen in footprinting. The respective function of the two proteins is not clear. As to initiation of aldolase B transcription, it might be regulated by both a TATA box and an initiator (Figure 1 ). Finally, Gregori et al. [60] showed that aldolase B promoter activity is strongly stimulated by the addition of sequences (IA in Figure 1 ) from the first intron.
Analysis of the chromatin structure revealed two DNAase I-hypersensitive sites upstream (-2.6 kb and -0.3 kb) of the cap site, two in the middle of the first intron, one in the eighth intron and two located 2.7 kb and 3.4 kb downstream of the polyadenylation site [60, 63, 64] . Only the site at -0.3 kb and the second intronic site are restricted to the tissues where the gene is expressed. These two sites correspond to the promoter and to the intronic regulatory element. Daimon et al. [63] investigated the methylation status of the gene and found a correlation between the expression of the gene and demethylation of Cyt-129 and of several cytosines in the first intron. The -129 nucleotide is located in the 'B' box described above.
Nutritional and hormonal control
This was investigated by Munnich et al. [65] and shown to differ in the three tissues expressing the enzyme. Starvation leads to a 10-fold decrease in mRNA concentration in liver and small intestine, but not in kidney. Refeeding the rats with a carbohydrate-rich diet restores normal mRNA levels, provided that the animals secrete glucocorticoid and thyroid hormones and insulin. The three hormones act in a permissive way since they are all inactive alone. Re-induction of liver mRNA is blocked by glucagon or cyclic AMP. In the small intestine, only insulin and thyroid hormones play a permissive role, glucocorticoids being dispensable. In addition, glucagon cannot inhibit re-induction of small intestine mRNA by carbohydrates. In the kidney, no effect of hormones could be monitored. Interestingly, refeeding rats with a fructose diet increases kidney mRNA levels and allows restoration of normal liver mRNA levels in diabetic rats. This suggests a role for fructose in the control of aldolase B expression. In cultured hepatocytes isolated from fasted rats, the transcription rate of aldolase B is stimulated by glucose together with insulin, but not by glucose or insulin alone [66] . The gene sequences that mediate this hormonal and nutritional control are unknown. [68] . The promoter contains a TATA box and binding sites for several transcription factors [69] (Figure 1) . A phorbol ester-response element (PMA in Figure 1 ), which binds a c-jun/c-fos heterodimer, is located at -1050 relative to the cap site. A C/EBP site is detected around -100 as well as upstream of the IRP-B site (see below), around -350. The latter C/EBP site was shown to bind purified C/EBPa in DNAase I footprinting experiments. However, in band-shift experiments with adipocyte extracts, this site binds a heat-labile protein distinct from C/EBPa, which is heat-stable. This protein is induced during differentiation from pre-adipocytes to adipocytes, and is referred to as gC/EBP. The proteins that bind to the IREs (IRE-A and IRE-B) are best described in the context of the insulin regulation of GAPDH gene transcription.
GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE
Nutritional and hormonal control GAPDH mRNA accumulates in adipocytes upon exposure to insulin and mRNA levels also increase in liver upon refeeding 6 F. P. Lemaigre and G. G. Rousseau after fasting [70] . The induction of GAPDH mRNA by insulin is tissue-specific, since it occurs only in lipogenic tissues. Secondly, it is differentiation-dependent since it occurs in mature adipocytes but not in pre-adipocytes [69] . Thirdly, both stable and transient transfection experiments in 3T3 adipocytes and hepatoma cells demonstrated that insulin stimulates transcription from the GAPDH promoter [71, 72] . Run-on experiments showed that the insulin effect occurs within 30 min and results from an increase in the transcription rate [71] . Deletion analysis located two IREs, from -488 to -408 (IRE-A) and from -408 to -269 (IRE-B). Study of the proteins that bind to IRE-A revealed that a protein, IRP-A, was induced in insulin-treated adipocytes as well as in liver upon refeeding after fasting. IRP-A binds to the 5' half of IRE-A and recognizes the CCCGCCTC core sequence [72] . By screening an expression library prepared from rat adipocytes with an IRE-A oligonucleotide, Nasrin et al. [73] 
Gene organization
In rats [75] and in humans [76] the L gene (9 kb) contains 12 exons. The first exon codes for the L'-specific amino acids, the second exon for the L-specific ones. A promoter is located upstream of each specific exon. Thus, the L-isoenzyme mRNA has a nucleotide sequence identical with that of the L' mRNA, except at the 5' end and for the 3' untranslated region. The sequence upstream of the fifth codon of the L mRNA is replaced in the L' mRNA by 98 nucleotides corresponding to an untranslated region followed by coding sequences [75] . The L' isoenzyme is therefore 31 residues longer than the L-type.
Tissue-specific control
Rat L promoter activity is regulated by sequences within 3.2 kb upstream from the cap site (Figure 1 ). Experiments with transgenic mice indicated that this region confers tissue-specificity to L promoter activity [77] [78] [79] . The promoter (-183 to +11) contains binding sites for HNF-1, NF-I, HNF-4, upstream stimulating factor (USF)-related proteins and L5-binding factors (Figure 1 ) [80] [81] [82] [83] . The HNF-4 site also binds chicken ovalbumin upstream promoter-transcription factor (COUP-TF)I and COUP-TFII [84] . The binding of HNF-4 apparently stabilizes NF-I binding [80] . The promoter corresponds to a liver-specific DNAase I-hypersensitive site HSS-1 [85] and suffices to confer tissue-specificity in vitro as well as in transfection and in transgenic mice [79, 81, 86, 87] . The most potent transcriptional stimulators are the liver-specific factors HNF-I and HNF-4. In transfection NF-I and USF in basal transcription is unclear [79, 86, 88, 89] . Yamada et al. [81] transfected hepatocytes in culture and proposed an activating function for USF, while Vaulont et al. [80] could not find any function for USF in vitro. The role of USF will be further discussed below. L5-binding factors are as yet uncharacterized proteins. The L5 sequence binds different proteins in liver and intestine [82] . Full understanding of their function awaits their purification since, depending on the experimental conditions, L5-binding factor displays activating [88] or inhibiting [81, 82, 89] properties.
The activity of the promoter is modulated by upstream sequences. Transient transfection of hepatoma cells [88] and the use of transgenic mice defined, between -2080 and -170, an extinguisher that is more active in intestine than in liver. This extinguishing activity could not be observed by transfection of hepatocytes in culture [88] . An activating region located around -3 kb is required for full promoter activity [79, 88] . This region corresponds to a liver-specific DNAase I-hypersensitive site (HSS-2) [85] [93] . Since Foufelle et al. [94] demonstrated that glucose must be converted into glucose 6-phosphate by a hexokinase to exert its action on gene transcription, Axel Kahn's group proposed that insulin is required for the production of glucokinase in hepatocytes while hepatoma cells may constitutively express hexokinases, thus bypassing the need for insulin [95] . Furthermore, the possibility that insulin action on transcription necessitates ongoing protein synthesis is suggested by Noguchi et al. [90] who showed that this insulin effect is blocked by cycloheximide. While cycloheximide may block the insulin induction of glucokinase, it also inhibits a step downwards in the pathway of glucose stimulation of transcription. Indeed, Lefranqois-Martinez et al. [93] showed that in their hepatoma cells the insulin-independent glucose stimulation of L promoter activity could still be blocked by cycloheximide. Insulin and glucose also stabilize the mRNA [96] .
Glucagon, acting via cyclic AMP, inhibits the effect of glucose and insulin in fasted rats and in cultured hepatocytes by decreasing the transcription rate and destabilizing the mRNA [91, 96] . Interestingly, Bergot et al. [89] showed that the cis-acting sequences that mediate inhibition by cyclic AMP are identical with those conferring stimulation by insulin and glucose. Thyroid and glucocorticoid hormones do not affect the transcription rate but exert a permissive effect on the dietary induction by acting at the post-transcriptional level [91] . Finally, fasting strongly reduces the intensity of the DNAase I-hypersensitive site HSS-1. This probably reflects an effect of diet-dependent hormones or metabolites on chromatin structure [85] .
Intense efforts have been devoted to identifying the cis-acting experiments COUP-TFI inhibits promoter activity. [100] .
The search for DNAase I-hypersensitive sites in the PEPCK gene, which aims at identifying broad regions involved in the liver-specific regulation, showed hypersensitivity at -6200, -4800, -1300, -400 to -30, +4650 and +6200 when the gene was investigated in rat H4IIE hepatoma cells. The sites located between -4800 and +4650 were observed only in cells expressing PEPCK [104, 105] . While the -400 to -30 region obviously corresponds to the promoter, the -4800 site, i.e. from -4902 to -4667, behaves as an enhancer [105] . Results from Faber et al. [106] did not support the possibility that methylation of CpG dinucleotides participates in the tissue-specific regulation.
The map of the PEPCK promoter, with the binding sites for basal, tissue-specific and hormone-dependent transcription factors, is shown in Figure 2 . Liver extracts produce eight DNAase I footprints, named cyclic AMP response element (CRE)-1 and -2, and P1 to P6 [107, 108] . P3 and P4 are divided into two and three subdomains respectively. Each element binds several proteins and block mutations disrupting the DNAase I footprints indicated that, under basal conditions, CRE-1 and P4 are the most potent stimulatory elements, followed by P1, P3, P5 and P6, and by P2 and CRE-2, which each contribute about 10 % of the activity of the promoter in vitro [108, 109] . Deletion analysis also indicated the presence of basal stimulatory (BSE in Figure 2 ) and inhibitory (BIE in Figure 2 ) elements, located close to the CRE-1 site. No protein-DNA interactions were detected on these two regions [108] .
Liver-enriched factors that recognize the PEPCK promoter include C/EBPa, C/EBP18, DBP, HNF-1, HNF-4 and probably HNF-3. Purified C/EBPa binds to a site downstream of the cap site [110] and to the CRE-1, P1, P3(I) and P4 (I-II) sites. The CRE-2 site is also bound by C/EBPa but only when high protein concentrations are used [111] . C/EBPa activates the PEPCK promoter through the P3, P4 and CRE-1 sites, and although it is recognized by C/EBPa, P1 does not mediate its activity. In addition, activation by C/EBPa via CRE-1 requires upstream sequences [111] . DBP binds to the CRE-1 and P3(I), and with a lower affinity to the CRE-2 and P2, sites [110] . Transfection analysis in human hepatoma HepG2 cells showed that DBP might activate the promoter and that the relative levels of C/EBPa and DBP could determine their respective activity [110] .
Furthermore, the -117 to -86 region apparently downregulates the activity of DBP [110] . Purified C/EBP/ binds to the same sites as C/EBPa, but displays a much higher affinity for the CRE-l site [112] . C/EBPfl also activates the promoter essentially through the CRE-1 site, but requires an intact P1 element. Like C/EBPa, C/EBP/J does not therefore activate transcription through all the sites to which it binds [112] . HNF-1 binds to the P2 element [107] and HNF-4 to the P6 element [113] . While both P1 and P6 positively regulate the PEPCK promoter, the individual functions of HNF-1 and HNF-4 were not investigated.
A potential HNF-3 site exists in the P3 (11) [108,11 5] . NF-I is involved in the P1 footprint [107, 108] . The P1 site is also detected in in vivo footprinting experiments, but only in cells expressing PEPCK [106] . The junlfos heterodimer binds avidly to the CRE-1 element and, with lower affinity, to the P2, P3 (11) and P4 elements [116] . When HepG2 cells are co-transfected with a jun expression vector and a PEPCK promoter-reporter gene construct, jun stimulates the PEPCK promoter through the CRE-1, P3 (11) ments it inhibits the activation of the PEPCK promoter byjun or by cyclic AMP. The inhibitory action offos requires the integrity of site P3(I) [116] . Fos is induced by insulin, and may therefore contribute to the dominant inhibitory effect of insulin. However, as Gurney et al. [116] pointed out, fos is also induced by cyclic AMP. This, in turn, could provide an explanation for the biphasic pattern of the cyclic AMP stimulation of the PEPCK promoter (see below). The initial cyclic AMP-mediated stimulation could be attenuated in the second phase by high levels of fos protein. The above-mentioned effects of fos and jun result from the overexpression of the proteins. The experiments therefore only address the question of the basal activity offos and jun.
In this respect, it is known that activation of PKC, e.g. by phorbol esters, modulates the activity of fos and jun through dephosphorylation and phosphorylation events. Interestingly, fos and jun do not seem to be involved in the response of the PEPCK gene to phorbol esters ([117] ; see below). Nuclear hormone receptors or hormone action mediators are discussed below.
Nutritional and hormonal control Fasting increases PEPCK expression, whereas refeeding a carbohydrate-rich diet lowers PEPCK to normal levels. The effects of diet are largely mediated by hormonal changes. It is therefore not surprising that transgenic mice carrying PEPCK constructs that confer hormonal response also show the expected response to dietary changes. In liver, the response to diet is provided by sequences from -402 to + 69 [99, 102] . Nevertheless, the dietary response may be partly independent from hormones. Indeed, addition of glucose to FAO cells or hepatocytes in culture induces a decrease in PEPCK mRNA levels. The maximal effect of glucose is reached after 2 to 4 h and results from an accelerated rate of mRNA degradation and from a decrease in the transcription rate. Administration of glucose to diabetic rats also decreases PEPCK mRNA levels in liver. Several examples of increased mRNA stability induced by glucose have been reported (reviewed in [118] ), but to our knowledge the regulation of the PEPCK mRNA by glucose is the only example of carbohydratemediated decrease in mRNA stability and transcription. Taken together, these results show that glucose, independently from insulin, inhibits PEPCK gene expression [119, 120] .
Insulin decreases the transcription rate of the PEPCK gene [121] and acts as an inhibitor of cyclic AMP and glucocorticoid induction [122, 123] . By stable transfection of hepatoma H4IIE cells with PEPCK-reporter gene constructs two IRS were located, one between -271 and + 69 and one between -416 and -402 [124, 125] . The latter IRS coincides with the accessory factor (AF)-2 binding site (Figure 2 ) discovered during the study of regulation by glucocorticoids ( [126] ; see below). Band-shift analyses with the AF-2 site as a probe show several complexes. The proteins involved have not been identified and none is induced by insulin. Since the AF-2 element is crucial both for glucocorticoid induction and insulin repression, O'Brien et al. [124] suggested that insulin could block glucocorticoid activity by disabling the function of AF-2.
Glucagon, acting through cyclic AMP, stimulates PEPCK gene expression. Glucose-refed rats, to which dibutyryl-cyclic AMP is administered, show an increased rate of PEPCK gene transcription in liver [127] . This effect can be reproduced ex vivo in H4IIE hepatoma cells, where cyclic AMP produces a biphasic activation pattern. After an initial burst of PEPCK promoter activity culminating after 30 min, the transcription rate decreases but remains 2 to 3-fold higher than the basal level. This effect does not require ongoing protein synthesis [122] . Several cisacting sequences within the PEPCK promoter mediate cyclic AMP activity [128] . The CRE-1, P3(I), and to a lesser extent P3(11) and P4, are involved in the cyclic AMP response. Mutations in the CRE-2, P2, P5 and P6 elements do not affect the activation by cyclic AMP [129] . Each of the sequences that mediate cyclic AMP effects binds several proteins. CRE-I is the only target for CREB in the PEPCK promoter [Ill] . C/EBPa, CEBP, and DBP also bind to CRE-1, but none of them mediates the cyclic AMP response through this sequence [112, 130] . The CRE-1 sequence, as well as the P3 and P4 elements, displays a weak cyclic AMP response on its own, but together these elements exert a synergistic activation [130] . The factors that confer cyclic AMP-responsiveness to the P3 and P4 elements are unknown. However, Roesler et al. [130] showed that administration of dibutyryl-cyclic AMP to rats increases C/EBP, mRNA levels in liver. This may explain the biphasic pattern of the cyclic AMP response. The sharp rise in promoter activity induced by cyclic AMP may be mediated by CREB, and the second phase of activity may be controlled by C/EBP/J. The way in which CREB mediates cyclic AMP activation results most likely from phosphorylation of the protein by PKA [112, 115] and does not imply an increased protein binding to the promoter, as shown in vitro and in vivo [115, 131] . This is consistent with the observation that cyclic AMP does not affect chromatin structure [104] . Cyclic AMP also induces stabilization of the PEPCK mRNA [132] . This effect does not require ongoing protein synthesis [133] but apparently involves a protein whose interaction with PEPCK mRNA is regulated by cyclic AMP-dependent phosphorylation [134] . Glucocorticoids stimulate PEPCK gene transcription in liver and repress it in adipocytes [122, 135] . The negative and positive responses to glucocorticoids are mediated through cis-acting sequences that are located in different regions of the gene [102] . This mechanism of differential response to glucocorticoids therefore differs from the one known to occur on the proliferin gene. In the latter case, positive or negative glucocorticoid regulation is mediated by a single GRU that binds different combinations of transcription factors depending on the physiological context [136] . The mechanism whereby glucocorticoids activate the PEPCK promoter in liver is complex and involves several proteins in addition to the glucocorticoid receptor. By transfecting hepatoma cells with PEPCK-reporter gene constructs, Imai et al. [126] characterized a GRU between -467 and -349. This region contains two binding sites for the glucocorticoid receptor (-395 to -349; GR in Figure 2) as well as the AF-l (-455 to -431, i.e. P6 footprint) and AF-2 (-420 to -403) sites. The proteins that bind to the AF-1 and AF-2 sites are uncharacterized.
The AF-1, AF-2 and glucocorticoid-receptor-binding sites are individually unable to respond to glucocorticoids. Full activity requires synergism between the four.elements. Glucocorticoid regulation also necessitates an intact CRE-1 site, and the unexpected physical interaction [137] between CREB and the glucocorticoid receptor, which bind 400 bp apart, might explain the CRE-1-GRU interaction. However, Xing and Quinn [138] showed that CREB supports the glucocorticoid induction, but through its effect on basal transcription rather than via a CREB-glucocorticoid-receptor interaction. An upstream sequence between -1264 and -1111 may also participate in glucocorticoid regulation [139] . The mode of action of glucocorticoids is unclear. Indeed, in hepatoma cells [122] and in vivo [127] , glucocorticoids exert a fast (30 min) and direct effect on the transcription rate. In isolated hepatocytes, however, glucocorticoids exert only a permissive effect on cyclic AMP induction. In the latter system, the effect is slow (16 h ) and blocked by cycloheximide [140, 141] . Finally, glucocorticoids stabilize PEPCK mRNA, an effect mediated by the 3' non-coding sequence [142] .
Loose et al. [143] demonstrated that thyroid hormones increase 6-fold the PEPCK transcription rate in thyroidectomized animals. In transfection of HepG2 cells with PEPCK-reporter gene constructs, T3 stimulates PEPCK promoter activity 3-fold through binding of the T3 receptor (T3R) to the -332 to -308 sequence [144] . Binding of the T3R to this site probably requires (an) additional factor(s) [145] . Activation by T3 also necessitates an intact P3(I) site. This enables one to locate the T3 response element (TRE in Figure 2) at the T3Ra and P3(I) sites. Since cyclic AMP and T3 synergistically activate the promoter, this synergy could involve the T3R binding site and the P3(I) element.
However, Lucas et al. [146] detected only a 2-fold effect of T3 in H411 cells and suggested that thyroid hormones may interfere with the effect of retinoic acid. Indeed, at low T3 concentrations the amounts of T3Ra in liver are high, T3Ra may heterodimerize with and inhibit the retinoic acid receptor (RAR)a and therefore decrease basal activation by RARa (see below). On the contrary, at high T3 concentrations, T3Ra levels are low and RARoc may activate the promoter.
Incubation of H4IIE cells with retinoic acid produces, within 1 h, a 3-fold stimulation of PEPCK gene transcription [147] . Transfection analyses located the retinoic acid response element (RARE) between -451 and -434 [147] . This sequence matches the P6/AF-1 sequence mentioned above. Purified RARa binds as a monomer or dimer to this sequence, but full activity of RARa requires the binding of a co-regulator to the RARE. This co-regulator may be retinoic X receptor a. Deletion of the AF-1 site does not completely prevent retinoic acid stimulation, suggesting the existence of a second RARE in the PEPCK promoter. Both all-trans and 9-cis retinoic acid activate the promoter [1 13] . Plasma retinoid levels normally remain constant.
It is therefore likely that the RARs regulate basal promoter activity. However, Pan et al. [148] showed that retinoic acid potentiates the effects of glucocorticoids and cyclic AMP.
Phorbol esters, like insulin, inhibit transcription of the PEPCK gene rapidly and without the need for ongoing protein synthesis. This effect is mediated by the -416 to -407 sequence (PMA in Figure 2 ), which coincides with the insulin-responsive AF-2 site. This region does not resemble any other known phorbol ester response element [117] .
Other regulators of PEPCK gene expression include the epidermal growth factor, which decreases mRNA levels in isolated hepatocytes [149] , and the tumour necrosis factor, which inhibits its transcription [150] . Finally, Beale et al. [151] established a close correlation between increased transcription rate and cuboidal cell shape, induced by high-density growth conditions.
Faber et al. [152] recently investigated the protein-DNA interactions in intact H4IIE cells by DNAase I protection. They detected not only nearly all the sites seen in vitro (Figure 2 ), but also additional sites between -510 and -500 and between -80 and + 29. Importantly, the in vivo DNAase I protection pattern was unaffected by, treatment with glucocorticoids, cyclic AMP or insulin.
CONCLUSIONS AND PERSPECTIVES
Only four of the eight genes that control, in the liver, key steps in the gluconeogenic and glycolytic pathways (namely those for glucokinase, PFK-2/FBPase-2, pyruvate kinase and PEPCK), and two of the seven genes encoding enzymes that catalyse reversible steps (namely aldolase B and GAPDH) have been characterized in terms of promoter regulation. Despite this limitation, it is interesting to compare the mechanisms involved in their tissue-specific and hormonal control.
All these genes except GAPDH are preferentially transcribed in the liver. For Figure 3 Liver-enriched transcription factors that regulate genes coding for glycolytic and gluconeogenic enzymes reviewed here belong to the five classes described so far (see Table 1 and Figure 3) . Members of more than one class bind to each promoter. Moreover, the PEPCK, L pyruvate kinase and aldolase B promoters, which contain a functional HNF-1 site, also bind HNF-3 or HNF-4. Since HNF-3 and HNF-4 stimulate transcription of the HNF-la gene [153] , and therefore occupy a higher position in the hierarchy of transcription factors, one could have expected that they need not bind to genes regulated by HNF-1. The fact that they do suggests a functional redundancy or a requirement in vivo for a co-operation between liver-specific factors to promote protein-protein interactions. There is no apparent correlation between the types of factors that interact with each gene and the function of the enzyme it encodes, i.e. glycolytic, gluconeogenic or amphibolic (Figure 3) .
A particular case among the liver-enriched transcription factors is the C/EBP family (Table 1) . McKnight et al. [154] suggested that C/EBP might be a central regulator of energy metabolism because it regulates genes coding for enzymes that control energetic processes in tissues involved in uptake, metabolism and storage of physiological fuels. Consistent with this hypothesis, we have seen that members of the C/EBP family regulate the PFK-2/FBPase-2, aldolase B, GAPDH, PEPCK, and perhaps glucokinase, promoters. Furthermore, the data on the PEPCK and GAPDH genes suggest that C/EBP proteins are involved in the mediation of cyclic AMP and insulin effects. However, we believe that the conclusions of McKnight et al. [154] were premature. First, other genes (e.g. albumin and transthyretin), not directly involved in energetic processes, are also regulated by C/EBP. Secondly, all C/EBP-family members do not display the same transcriptional properties, and most often the C/EBP isoform was not identified. Previous reviews [3, 4] mouse liver [155, 156] and decreases FBPase-l mRNA in rat liver [157, 158] (Figure 4) . We (Table 3) . Likewise, the cis-acting sequence involved in the transcriptional inhibition of the glucagon gene by insulin resembles that involved in the stimulation by this hormone of GAPDH gene transcription (Table 3) . Since it is known that the same cis-acting sequence and trans-acting factor can mediate stimulation or inhibition of gene transcription, depending on the promoter and cellular context (e.g. the glucocorticoid receptor [136] ), this may apply to the effects of insulin discussed here. Still, it is clear that the molecular mechanism of the transcriptional effects of insulin on the genes reviewed here is not univocal.
Cyclic AMP opposes the action of insulin since insulinstimulated genes are repressed by cyclic AMP and vice versa (Figure 4) . Only the PEPCK gene among those described here has been studied in terms of cyclic AMP action. The cyclic AMP stimulation of this gene is mediated by CREB and members of the C/EBP family. Which member of this family is involved and how its activity is modulated by cyclic AMP is unknown. C/EBP/J may be a good candidate since it mediates the stimulation of the c-fos gene by cyclic AMP [164] . The mechanism by which cyclic AMP inhibits transcription of genes coding for glycolytic enzymes has not been elucidated. Still, the GlRE of the pyruvate kinase gene promoter is required for inhibition by cyclic AMP. PKA could inhibit, directly or indirectly, the b-HLH factor that mediates the insulin (i.e. glucose) effect, or it could activate a repressor that binds to the pyruvate kinase GIRE. The work of Burgering et al. [165] is relevant to this issue, as they showed that in fibroblasts cyclic AMP interferes with the insulin signalling pathway at a site downstream of p21ra8 but upstream of the raf-1 kinase.
In liver, glucocorticoids stimulate transcription of the gene coding for PEPCK, a gluconeogenic enzyme, and of the gene coding for glucokinase, a glycolytic enzyme. These paradoxical effects can be reconciled by considering the physiological role of glucocorticoids in carbohydrate metabolism. During fasting, they help to maintain glycaemia by exerting a permissive effect on the glycogenolytic hormones that act via cyclic AMP and they promote gluconeogenesis through increased amino acid uptake in liver and increased activity in this tissue of transaminases, PEPCK and glucose-6-phosphatase. In contrast, in the postprandial state, glucocorticoids help to store glucose as glycogen and to dispose of the excess through the glycolytic pathway. In this situation, glucocorticoids, together with thyroid hormones, play in liver a permissive role on the action of insulin whose concentration is high. Thus it is not surprising that glucocorticoids stimulate also, like insulin, the glucokinase, aldolase B and PFK-2/FBPase-2 genes. Although the latter codes for a bifunctional enzyme, its stimulation in liver increases fructose 2,6-bisphosphate [44] , which is a stimulator of glycolysis.
It is noteworthy that the hormone actions discussed here display a tissue-specific pattern. Proteins that are thought to mediate the insulin response of the GAPDH gene and the glucose response of the pyruvate kinase gene bind in the vicinity of a tissue-specific factor. IRP-B binds close to a C/EBP site on the GAPDH gene, and the USF-related protein requires binding of HNF-4 to the pyruvate kinase promoter. This suggests that a functional interaction between the two proteins confers a tissuespecific response to glucose or insulin. Cyclic AMP also plays a role in the liver-specificity of expression of gluconeogenic genes. Hybrids of different cell types may fail to express the tissuespecific products of either parent. This led to the definition of tissue-specific extinguisher loci (reviewed in [166] ). The Tse-J locus is responsible for the extinction of the PEPCK, tyrosine aminotransferase and aldolase B genes in hybrid cells [167] . The product of the Tse-J locus is the regulatory subunit RIa of PKA [168, 169] . Rla is expressed in many cell types but at a 50-fold lower level in the liver. Overexpression of Rla in hybrid cells lowers the activity of the catalytic subunit of PKA and, as a consequence, reduces phosphorylation ofthe transcription factors that mediate the action of cyclic AMP. Contrary to the PEPCK and tyrosine aminotransferase genes, the aldolase B gene is inhibited by cyclic AMP and yet it is downregulated by Tse-I/Rla. This paradox has not been explained. Liver-specific glucocorticoid hormone action on the tyrosine aminotransferase gene has been well documented by Nitsch et al. [170] who demonstrated that HNF-4 may co-operate with the glucocorticoid receptor and so induce liver-specific glucocorticoid stimulation of transcription. Similarly, the proximity of the binding sites for the glucocorticoid receptor and for HNF-4 on the PEPCK gene suggests that these proteins may co-operate in the glucocorticoid response.
Although this review deals primarily with transcriptional control, we have mentioned that the expression of the genes that regulate glycolysis and gluconeogenesis is also regulated through changes in the stability of their mRNAs. Little is known about the latter mechanism. As T3 and (or) glucocorticoid hormones stabilize the mRNAs for PEPCK, GAPDH and pyruvate kinase, and cyclic AMP destabilizes PFK-2/FBPase-2 and pyruvate kinase mRNA, these may be excellent models to study the hormonal control of mRNA degradation. Also, glucose exerts opposite effects on the stability of the PEPCK and glucokinase mRNAs. This may indicate the existence of a co-ordinate control of mRNA degradation.
Although our knowledge on the transcriptional control of genes that regulate glycolysis and gluconeogenesis has significantly improved recently, several aspects deserve further investigation. First, the long-term control of the glucose/glucose 6-phosphate substrate cycle remains ill-defined, since few results are available regarding the cis-trans regulation of the glucokinase and glucose-6-phosphatase genes despite the recent cloning of the latter [171] . Secondly, while the outlines of the control of the PFK-l/FBPase-l cycle are known, again data are lacking on its transcriptional regulation. Thirdly, the liver-specific factors that regulate transcription of the genes described here have been fairly well identified in vitro. How they stimulate transcription in vivo and how they interact with other transcription factors remains to be found. Finally, the transcription factors that mediate insulin and glucose action on these genes are still to be purified and cloned. This is also a prerequisite for understanding how insulin action is facilitated by glucocorticoid and thyroid hormones and is inhibited by cyclic AMP.
